Y. Bécouarn

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy, Françoise Desseigne, Marc Ychou et al. · New England Journal of Medicine · 2011 · 7.6K citations · Full text

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Thierry Conroy, Jean-François Bosset, Pierre-Luc Etienne et al. · The Lancet Oncology · 2021 · 1.2K citations

Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2

Jean‐Pierre Gérard, D. Azria, S. Gourgou-Bourgade et al. · Journal of Clinical Oncology · 2010 · 747 citations

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

S. Gourgou-Bourgade, Caroline Mollévi, Françoise Desseigne et al. · Journal of Clinical Oncology · 2012 · 480 citations · Full text

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

Philippe Rougier, R. Bugat, Jean‐Yves Douillard et al. · Journal of Clinical Oncology · 1997 · 429 citations